Summary An analysis of prognostic factors has been performed on 260 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and laboratory parameters have been studied, including variables reported to be important indicators of prognosis in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment of complete remission (CR) was the most important predictor of overall survival, low serum lactate dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced stage disease, constitutional symptoms, increasing patient age, a lovy serum albumin and the presence of bulk disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free survival, and reduced overall survival following CR. There was no significant correlation between histological subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology NHL.
Over the past decade durable remissions have been achieved in an increasing proportion of patients with high grade NHL and there is evidence that remission rates and survival may be improved by using intensive chemotherapy (Fisher et al., 1983; Klimo & Collins, 1985 ; Laurence et al., 1982; Blackledge et al., 1980) . A more aggressive approach to treatment in this disease is inevitably associated with an increased toxicity and a greater requirement for supportive resources. Clearly an accurate pre-treatment prognostic assessment of patients is required to guide the clinician in the selection of the most appropriate treatment schedule. Currently, in high grade NHL, therapeutic policy is determined predominantly by the extent of disease as defined by the Ann Arbor staging system (Carbonne et al., 1971) , and this system has continued to be employed despite our recognition that it harbours some important discrepancies (Rosenberg, 1977) . In this study we have set out to reassess the prognostic relevance of the Ann Arbor system in high grade NHL and, further, have attempted to identify additional patient characteristics and disease parameters which may be used in conjunction with the Ann Arbor system to improve our prognostic evaluation of patients.
Retrospective studies performed over the past 10 years have reported a number of factors having influence on prognosis in high grade NHL. However, the interpretation of data from many series has been hampered by small patient numbers and the fact that only few centres have employed multivariate analyses (Jagganath et al., 1985; Armitage et al., 1982; Steward et al., 1984; Todd et al., 1986; Shipp et al., 1986; Fisher et al., 1981; Koziner et al., 1982) . Comparison of results from different studies is further compromised by the lack of uniformity in the variables analysed, and in many publications the potential prognostic factors investigated are not clearly listed.
In an attempt to re-examine the prognostic evaluation of patients, we have collected data, including all variables previously reported as having significant prognostic importance in high grade NHL, and subjected these data to multivariate analysis. (Blackledge et al., 1980) . The remaining patients with stage I and II (non-bulky) disease received initial radiotherapy and were subsequently randomised to receive either adjuvant VAP or 3-weekly cycles of CMOPP (cyclophosphamide, mustine, vincristine, procarbazine and prednisolone) (Wagstaff et al., 1987 (Isaacson et al., 1985) . In addition the diffuse unclassified category includes some cases of probable T-cell lymphoma, but data from immunophenotyping are not included in this paper. (Kaplan & Meier, 1958) , and these curves were compared using the log rank test (Peto & Peto, 1972 ). Cox's proportional hazards model (Cox, 1972) was used to determine the most important prognostic variables. A stepwise logistic regression procedure was performed to determine combinations of patient characteristics and disease parameters important in predicting CR. The data from continuous variables were examined to ensure that there was a linear relationship between the absolute value of the variable and prognosis. Continuous variables relating to biochemical measurements were transformed by taking logarithms. Missing covariate data were handled by the introduction of a dummy variable to indicate the presence or absence of information on a particular variable.
Results
Factors having a significant relationship with prognosis (attainment of CR, RFS or survival) using univariate analysis are listed in Table IV . Treatment schedule did not prove to be a significant prognostic factor in terms of overall survival, RFS and survival following CR in multivariate analysis.
Overall survival
The median survival for the 260 patients was 53 months (Fisher et al., 1981; Armitage et al., 1982; Steward et al., 1984 (Kaminski et al., 1986) , reporting on 148 patients with localised large cell lymphoma treated with initial radiotherapy, found only a borderline difference in 5-year survival rates between stage I (56%) and stage 11 (48%), and they showed a poor overall survival to be associated with extralymphatic involvement, 'large' volume disease (>10cm), age >60 years and gastrointestinal involvement. A study of prognostic factors in stage I and II disease by our own group has shown GI involvement, bulk disease and serum albumin to be important (Mackintosh et al., 1988) . The prognostic value of the Ann Arbor distinction between stage III and IV disease remains uncertain. Several studies have reported similar survival figures for stage III and stage IV patients (Koziner et al., 1982; Jagganath et al., 1985; Todd et al., 1986; Laurence et al., 1982; Sweet et al., 1980) , but Nathwani et al. (1982) (Bierman et al., 1957; Ferraris et al., 1979; Jagannath et al., 1986; Schneider et al., 1980; Hagberg & Siegbahm, 1983) . In this study, although serum LDH was shown to be an independent (Christensson et al., 1986; Morgan et al., 1986; Juneja et al., 1986 ), but few have investigated the prognostic significance of DNA content within the category of high grade lymphoma. In concordance with two other series (Bauer et al., 1986; Young et al., 1987) appear surprising in the context of the increased sensitivity of cycling cells to ionising radiation and cytotoxic drugs. However, other factors associated with high proliferative rates may play an important part in tumour response. These include neoplastic cell repopulation between courses of chemotherapy or between fractions of radiotherapy, and the increased probability of the emergence of 'resistant' clones in high proliferative tumours. In contrast to the series from Chicago and Sydney, the association of PI with response rate in our study did not translate to a significantly reduced overall survival. In a prognostic factor analysis encompassing patients of all stages, it is assumed that similar prognostic factors apply irrespective of whether the disease is localised or advanced. This, however, may be inaccurate, and the prognostic impact of a particular variable may manifest in only a subgroup of patients, and be masked when examining the total patient population. The data from patients with stage I and II disease and those with stage III and IV disease have been reanalysed separately, and the results will be published (Mackintosh et al., 1988; Cowan et al., in preparation) .
This study serves to illustrate the prognostic importance of the Ann Arbor staging system in patients with high and intermediate grade NHL and has demonstrated factors which when used in conjunction with clinical stage improve our prognostic assessment of patients.
